Exact claim · Version 1 · Reviewed 2026-07-23
“Because teduglutide promotes intestinal growth, it is low risk.”
A verdict on this wording and scope, not a universal grade for Teduglutide.
01 · Verdict
Misleading
The same biological activity underlies important warnings, including potential acceleration of neoplastic growth.
- Evidence basis
- Regulatory or product record
- Scope
- Approved Gattex use with required screening and monitoring.
- Category
- Safety
02 · Primary record
Check the attached evidence
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.